The Clq inhibitor, ClqI, an -30-kD circulating chondroitin4 sulfate proteoglycan, displayed concentration-dependent prolongation of plasma and fibrinogen solution clotting times. Under factor XIIIa catalyzed cross-linking conditions and maximum ClqI concentrations, minor amounts of clot formed displaying complete 'y-y dimer formation but virtually no a-polymer formation. The anticoagulant effect was undiminished by its binding to Clq, by increased ionic strength, and by CaCI2, but was abolished by incubation of CiqI with chondroitinase ABC. '251-labeled CiqI bound to immobilized fibrinogen, fibrin monomer, fibrinogen plasmic fragments D1 and E, and fibrin polymers. Occupancy on the E domain required uncleaved fibrinopeptides together with another structure(s), and it did not decrease binding of thrombin to fibrinogen. Occupancy on the D domain did not decrease the fibrinogen binding to fibrin monomer. We conclude that the E domain occupancy impaired fibrinopeptide cleavage, and occupancy on the D domain impaired polymerization, both steric hindrance effects. C1qI binding to fibrinogen explains at least in part the well-known fibrin(ogen) presence in immune complex-related lesions, and the fibrinogen presence in vascular basement membranes and atheromata.
Introduction
Fibrinogen is a plasma glycoprotein containing three pairs of polypeptide chains Aa, By3, and y interlinked by disulfide bridges which are clustered in three regions, the central or E and two outer or D domains ( 1 ). It is converted to fibrin monomer by cleavage of two small amino-terminal peptides, A and B, by thrombin-A from its Aa and B from its B(3 chain, respectively. Fibrin monomers spontaneously polymerize to form the gel matrix, which is further stabilized by the formation ofcovalent links catalyzed by factor XIIIa. Polymerization is initiated by the binding of one fibrin E domain to the D domains oftwo other fibrin molecules thus forming a two-molecule-thick strand, the protofibril.
Glycosaminoglycans (GAG)' are present in blood in concentrations of -5 sg/ml (2) . One fourth or fewer of these circulate in free form, and the remainder are bound to unidentified proteins. GAG heterogeneity (3) , their presence in numerous sites (4) such as cell membranes and basement membranes, and their release from cells in culture (3, 5) suggest multiple sites of origin. The major form in human plasma (2, 4) is the low sulfated chondroitin-4 sulfate proteoglycan (C-4SP), which consists of repeating disaccharides of glucuronic acid-N-acetyl-galactosamine, generally bound to the hydroxyl group of a serine residue of a core peptide to give the sequence (disaccharide)nGlcUA-Gal-Gal-Xyl-O-Ser. These repeating disaccharides are sulfated to a variable degree, a variation that modifies interactions (5) with other molecules. The discovery that a polyanionic molecule(s) was associated with isolated C I q (6) , the first component ofcomplement, led to its identification (4) as a heterogeneous population of C-4SP that displayed potent inhibition of the hemolytic activity of Clq (4), whether it was isolated from serum (4, 6) or from lymphocyte membranes (7) . The known interaction of fibrin with tissue glycosaminoglycans (8, 9) , and the increased circulating concentrations ofproteoglycans in certain pathologic states (2) led us to examine the possible interactions between Cl qI and fibrinogen/fibrin [ fibrin(ogen)]. Initial results disclosed binding to and an anticoagulant property against fibrin(ogen) by ClqI. This formed the subject of the present investigations.
Methods
Fibrinogen, fibrin, andplasmicfragments. Fibrinogen was isolated and its concentration was determined as described (10) . Fibrin monomer preparation and polymerization ( 11 ) and SDS-PAGE ( 12) were performed as described. Polymerization rates were computed from the time course of clot absorbance at 350 nm, and clot turbidity maxima were obtained as described (11) . Batroxobin and human thrombin were kind gifts from Dr. K. Stocker (Pentapharm Ltd., Basel, Switzerland) and Dr. J. Jesty (Health Sciences Center, SUNY, Stony Brook, NY), respectively. Hirudin (Sigma Chemical Co., St. Louis, MO) and D-phenylalanyl-prolyl-arginyl chloromethyl ketone (P-PACK) (Calbiochem Corp., La Jolla, CA) were used as provided. Plasmic fragments D, and E were isolated and their concentrations were measured by procedures previously applied ( 11) . Plasma coagulability was measured by adding -50-200 ,ug of 1251I-labeled fibrinogen ( 11) per milliliter ofplasma, and by obtaining thrombin (1 U/ ml)-induced clots, at ambient and then at 41C temperatures for 1 h and several hours, respectively. The counts per minute (cpm) ofsynerized clots and their supernatants (> 90% of original volume) were obtained in a 'Y counter. 1251.
labeled C I qI (vide infra) clot binding was obtained either by incorporation before clotting or by immersing the clot in the ClqI solution overnight. To obtain cross-linked clots the buffer, Tris-HCI, pH 7.4, g = 0.15 contained factor XIII 5-40 nM, 2-30 mM CaCl2, 0.1 U/ml human thrombin, and Kunitz pancreatic trypsin inhibitor KPTI (FBA Pharmaceuticals, West Haven, CT) 100 U/ml. In some experiments, clots were obtained by dilution of preformed fibrin monomer solutions with this buffer ( 11 ) in the presence or absence of C IqI. Under these conditions factor XIIIa activity measured by the monodansyl cadaverine assay ( 13) was unaffected by ClqI (n = 2). Chondroitinase ABC, which cleaves galactosaminoglycan side chains from C-4SP, and chondroitin sulfate A (a core-free C-4SP carbohydrate side chain component) were used as supplied (Sagakaku America Inc., Rockville, MD). Fibrinopeptide measurements were performed by HPLC (14) . For binding measurements, CIqI was added to solutions containing [3] [4] [5] ,ug/ml of A + B peptides (each in roughly equal concentrations), vortex-mixed, and filtered after 5-10 min via a 10,000 mol wt cutoff(Millipore Corp., Bedford, MA) filter. This removed ClqI which otherwise appeared as a single protein peak near the start of the HPLC acetonitrile elution.
CiqI isolation and related analyses. Cl qI was isolated essentially as described (6) , and its electrophoretic (SDS-PAGE) bands could not be stained with Coomassie Brilliant Blue dye. It was subfractionated by size exclusion chromatography to obtain the active moiety ( 15) . The Cl qI concentration was determined by using a Bosch and Loemb (Leica Inc., Buffalo, NY) refractometer; thereafter, the calculated extinction coefficient A (1%, 1 cm at 280 nm) of the active chromatographic isolate, 2.8 (range 2.6-3.0, n = 3) was used. The isolation procedure can be summarized as follows. Serum containing 1 mM EDTA, pH 7.5, q = 0.16, was incubated at 370C for -10 min to dissociate Clq from Clr and Cls. This was diluted to a final concentration of 1 = 0.04, followed by stirring at 4VC for at least 20 min to precipitate Clq. The centrifuged (4°C) precipitate was washed thrice in buffer containing 5 mM EDTA to remove contaminants, and allowed to dissolve in 0.7 M NaCl overnight. Material remaining insoluble was discarded, and the remaining solution was dialyzed against 100 mM EDTA, pH 5, ,u = 0.078. The precipitate was removed by centrifugation ( 16, 000 g, 30 min, 4C), washed twice in cold buffer excess, and dissolved in 300 mM NaCI, 5 mM EDTA, pH 7.5. This solution, further centrifuged to remove insoluble material, was dialyzed in barbital buffer, / = 0.5, pH 8, and 1 mM each of CaC12, and MgCl2. The solution was subjected to Con A-Sepharose (Pharmacia-LKB, Piscataway, NJ) chromatography, harvesting the inhibitor in the unbound eluate (and Clq by subsequent elution with 10% methyl-a-o-mannopyranoside, Sigma Chemical Co.). The unbound fraction was subjected to HPLC ( 14) exclusion chromatography (TSK columns, Beckman Instruments, Inc., Palo Alto, CA), pH 7.4, A = 0.15. The protein peak displaying inhibition against the Clq hemolytic activity amounted to -15% oftotal protein and was examined for its effect on fibrinogen clotting. Possible contaminant Con A contributing to the effects on fibrin ( ogen) was excluded by one C l qI preparation that was exposed overnight to solid phase (Sepharose-bound, Sigma Chemical Co.) anti-Con A IgG antibody. Its inhibition against fibrin gelation was undiminished by this exposure. For CIqI digestion, chondroitinase ABC was added to a solution of radiolabeled or unlabeled ClqI, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] ,ug/ml, pH 8, to achieve 30 mU/ml and incubated overnight, 37°C.
The mixture also contained 10 gg/ml pepstatin, 20 ,g/ml leupeptin (Calbiochem Corp.), 1 mM benzamidine, and 2 mM o-phenanthroline (Sigma Chemical Co.). The mixture was heated at 900 for 1 min and tested for fibrinogen clotting effects either directly or after dialysis against the testing buffer. This heat exposure of untreated Cl qI control did not decrease its fibrin binding or its effect against fibrin polymerization (n = 2). Lack of degradation of fibrin was ascertained by demonstrating no change in the polymerization rate, clot turbidity, and its SDS-PAGE bands (11) .
Assay ofClqI activity. Solutions containing CIqI were tested by a hemolytic assay using Clq-deficient or Clq-depleted (ClqD, Quidel, San Diego, CA) serum as described (16, 17) . Briefly, isolated Clq (5-10 gg/ml) was mixed with various concentrations ofClqI in a final volume of 300 pi of veronal buffer, pH 7.5, adjusted to , = 0.15 with NaCI, containing CaCl2 1.5 mM, MgCl2 5 mM, and 0.1% gelatin).
After 30 min at 370C, 10 ,l ofC I qD serum and 200 ,l of 1.5 X 10-8/ml sheep erythrocytes sensitized with specific antibody were added and incubated for a further 60 min at 370C; 1 ml of cold buffer was then added to stop the reaction and the hemoglobin released in the supernatant was assayed spectrophotometrically at 412 nm. The C I qI activity was computed as percentage of the C Iq control hemolytic activity.
Production and isolation ofantibody. Monospecific polyclonal antibody was raised in rabbits by multiple subcutaneous and deep intramuscular injections of 100-200 ,gg/ ml C IqI suspended in complete Freund's adjuvant which had been diluted with incomplete adjuvant 1:2. The second set ofinjections was given 2 wk later by the same route, with ClqI suspended in complete/incomplete adjuvant ratio of 1:4. Subsequent injections were made in incomplete adjuvant at 2 wk intervals; 6 wk after the fourth injection date a final injection was given and the rabbits were bled 10 d later. IgG was isolated using the ImmunopPure A/G IgG purification kit (Pierce Chemical Co., Rockford, IL) according to the manufacturer's procedure, and was assayed by radial immunodiffusion. A single precipitin arc was shown against Cl qI and there was no cross-reactivity with Clq and with Con A. The isolated IgG neutralized the capacity of ClqI to inhibit the Clq hemolytic activity.
Radioiodination and measurements. '25I-labeling was carried out ( 11 ) as described, and specific activities were > 60 X I03 cpm/ng protein. Autoradiograms and densitometry were obtained on dried polyacrylamide gels by using X-ray film (Eastman Kodak Co., Rochester, NY) and a (Pharmacia-LKB) laser densitometer equipped with a recorder, respectively.
Binding assays. These were carried out using buffer, pH 7.4, A = 0.15, containing KPTI 100 U/ml throughout. Fibrinogen solution, 50 glg/ml, pH 7.4, was added to polystyrene (Immulon Removawell, Dynatech Laboratories, Alexandria, VA) miniature test tubes (i.e., removable microwells or microplates) in 60-or 70-,d aliquants and left covered in a moist chamber overnight at ambient temperature or for 2 h at 37°C. The solution was then replaced with human serum albumin 50 ,ug/ml for at least several hours; it was then removed and the tube washed thrice with excess buffer; the desired ligand was then added and after incubation this washing procedure was repeated, but the final wash was performed five times and the buffer contained 0.05% Tween 20. Residual wash liquor was carefully removed using a micropipette. Under these conditions 1.4 pM of fibrinogen and 0.4 pM Clq bound to each microwell, calculated from a 1:50 mixture of ( 125I-labeled/unlabeled protein, n = 7). To prepare fibrin monomer thrombin 0.1 U/ml or batroxobin 0.5 U/ml, containing KPTI, 200 U/ml, was left for several or more hours. This was then replaced for 30-60 min with enzyme neutralizing buffer (50 tg/ml albumin) containing P-PACK 50 nM or hirudin 5 U / ml to neutralize thrombin, or PMSF 100 nM, to neutralize batroxobin.
Results

Investigations of whole CiqI
In pilot experiments, several C lqI isolates separated from C lq by the Con A chromatographic procedure prolonged the thrombin clotting times of plasma and of isolated fibrinogen solutions. For example, one CiqI isolate (at 38 8sg/ml, pH 7.4) decreased the thrombin (0.2 U/ml) induced polymerization rate of fibrin (2 ztM, pH 7.4) from 2.6 to 1.38 (XI0-3/s (see Methods) . A similar inhibition was demonstrated by soluble fibrin monomer induced to polymerize (n = 4). Addition of C lqI to plasma in further investigations resulted in invariable delay in clotting times which was concentration dependent, demonstrable in either heparin or citrate-anticoagulated plasma, in the presence (Table I) or absence of CaC12, and whether clotting was induced by thrombin, batroxobin, or ancrod (not shown). Clots formed and were partly or fully soluble in urea (n = 4). SDS-PAGE analyses (n = 2) disclosed the (Fig. 1 D) , were normalized when the ClqI solution had been treated with chondroitinase ABC (see Methods, n = 2), consistent with its known proteoglycan structure (6) . Moreover, preincubation ofClqI with either a polyclonal anti-C lqI antibody (n = 2, see Methods, not shown) or with C lq (Fig. 1 C) Ciql /lg/ml were parallel (Fig. 3) , indicating the two inhibitors acted independently against fibrin polymerization. These results were consistent with those from binding experiments (vide infra) and are considered further in the discussion section.
Fibrin (ogen) binding studies. SDS-PAGE autoradiograms
of '25I-C lqI disclosed that, like the parent material, the amounts bound to Clq as well as those bound to fibrinogen were approximately three-to fivefold higher than those bound to either albumin or IgG controls (n = 5). Similarly, the autoradiograms disclosed that eluates from either immobilized fibrinogen or Cl q disclosed the same electrophoretic bands, a major 30-kD and minor bands of 28 and 21 kD (Fig. 2 B) , thus establishing that the same molecular species possessed the two distinct inhibitory properties, one against C lq and another against fibrin(ogen). The presence of EDTA (2 mM) resulted in no change in C lqI binding to either fibrinogen (n = 6) or fibrin (n = 6). Also, the amounts of C lqI bound to fibrinogen (n = 6) did not change when the ionic strength was increased from 0.15 to 0.5, consistent with similar results ( vide supra) on its inhibition of fibrin polymerization, but in sharp contrast to its known failure to bind to Clq at high ionic strength (4 (Table II) , disclosed ClqI binding to all three forms but in respectively decreased amounts. Also, fibrin (1 uM) clots immersed overnight in 6.7 MAM Cl qI bound 68% of C lqI (n = 4), indicating that C lqI binding sites remained available in polymerized fibrin. These results led to assessment ofbinding to isolated plasmic fragment E of fibrnogen. Fragment E also bound C lqI (Table II) Clq inhibitory activity, vide supra) suggested they were species with no inhibitory activity against Clq. Alternatively, they were inhibitory but lacked the antigen epitope possibly reflecting either fragments of a larger (e.g., 30 kD) species or other unrelated forms. Nevertheless, they typically did not stain with Coomassie Blue and were assumed to be C-4SP in accord with the known characterization of the parent material (4). 20 25 of the uncleaved B peptide was clearly indicated by comparisons of ClqI binding to dessAA and desAA/desBB fibrin monomers (Table III) , and by results indicating cleaved B peptide bound to liquid phase Cl qI (vide infra). To explore the C lqI binding to the intact E domain, immobilized fibrinogen containing bound 1251-C I qI was exposed to thrombin ( 1 U / ml, overnight). This resulted in no release of C lqI (n = 6). Also, '251-thrombin was exposed to fibrinogen containing bound C lqI (n = 6), and the amounts of thrombin bound, did not differ from those bound to fibrinogen controls whether or not thrombin had been inactivated by P-PACK.
Binding to fragment D, was also demonstrated (Table II) . Clql gL g/ml For example, a solution containing -10 ,ug C 1qI/ ml, 2 ,tg of A, and 2 ,g of B/ml yielded no free A or B peptides (n = 3).
That is, when such solution mixtures were applied whole or after microfiltration to remove Cl qI (see Methods), no free peptides were detectable in the filtrate, in sharp contrast to control solutions lacking ClqI. Moreover, the amounts of free peptides were inversely proportional to the ClqI concentration (Table III) . Also, using a single A and B peptide solution mixture higher C lqI concentrations were required to remove peptide B than those which removed peptide A or AP (n = 3), peptide AP requiring the lowest concentrations of ClqI for removal (not shown). Calculated from such data, a single mole of ClqI displayed a capacity to bind at least 1 mol ofpeptide A and 0.7 mol of B from the same mixture. Since the amounts of AP peptide were minor (i.e., < 20% of A) this was not separately calculated.
Discussion
The most important findings of the foregoing investigations relate to the capacity ofClqI to bind to fibrin(ogen) either free and in complex with Clq and to impair fibrin gelation in plasma. The plasma results indicated that C lqI binding to fibrinogen was selective among other proteins, shown by the binding of much lower amounts to isolated albumin and IgG. Moreover, the circulating form of (i.e., Clqrs complex) does not bind ClqI (7). Because most circulating proteoglycans are protein bound (2, 4) our results suggest that fibrinogen is a major binding protein in normal plasma; anticoagulant effects by such proteoglycans could not be expected owing to their low concentrations (< S gg/ml [2] ), their estimated maximum binding of 6.7 mol/mol fibrinogen (vide supra), the at least 20- (Fig. 3) . Additional evidence of steric hindrance was provided by use of ClqI concentrations which allowed partial insoluble gel formation. All y chains formed y-,y dimers (Fig. 2 A) indicating complete oligomer or protofibril formation. However, little or no a-polymers formed, shown in Fig. 2 A, indicating progression to more complex polymer forms could not be demonstrated. This implied that occupancy of fibrin E by the D domains of two other monomers (i.e., linear polymerization) was not impaired, notwithstanding that it may have occurred slowly. However, lateral or a chain dependent polymerization was either prevented or possibly occurred by misalignment which prevented formation of covalent crosslinks containing a chains.
Unimpaired thrombin binding along with the potent effect against fibrin polymerization by ClqI, raises possible in vivo implications. It may, for example, provide an enhancement of the anticoagulant state of the relatively self-contained inflammatory or tissue repair microenvironments in the presence of saturated inhibitors such as AT III. Even where limited concentrations of fluid phase C IqI exist whether or not it is bound to Clq/antibody complexes, ClqI does bind to fibrinogen and to fibrin serving to further limit thrombogenesis. Clearly, such complexed fibrin(ogen) still binds thrombin serving to further enhance the anticoagulant state. Furthermore, such binding to immune complexes may explain the long known presence of fibrin(ogen) in immune complex-related pathologic lesions. Reported binding ofClq to fibrinogen ( 19) appears to be independent ofthe ClqI effect. That is to say, neither the anticoagulant effects nor the binding of C lqI could be diminished by its preincubation of or in the presence of molar excess of Cl q (vide supra). In that report a different C I q isolation procedure was used and it is unclear whether a possible effect by undesorbed ClqI played a role, if any. Whether or not membrane intercalated or other solid-phase proteoglycans bind fibrinogen is an open question. A report on thrombomodulin (20) , a thrombin inhibitor residing on endothelial cell membranes, is of interest in this regard, in that enzymic removal of the sulfated GAG moiety of rabbit thrombomodulin abolished its anticoagulant activity against thrombin fibrinogen clotting, intimating an effect similar to that of the present proteoglycan.
Among other possible in vivo roles suggested by the results, one relates to cell receptor binding of fibrinogen. Certain fluidphase chondroitin sulfate proteoglycans reportedly (5) inhibit receptor interaction with ligand, particularly as it relates to extracellular matrix proteins, or they may inhibit cell-cell interaction (21 ) . Conversely, membrane intercalated proteoglycans mediate cell-matrix and cell-cell interactions; melanoma cells, for example, failed to interact with the extracellular matrix when their chondroitin sulfate proteoglycan synthesis was blocked (22) , leading the authors to suggest a cooperative role between cell receptors and such membrane proteoglycans. Since fibrinogen and fibrin are native occupants of such extracellular sites early on during thrombus repair, their interaction with cell membrane proteoglycans may play a role in receptor mediated cell transit within the thrombus.
A mechanism for the presence of fibrinogen in atherosclerotic lesions (23) (24) (25) (26) can be formulated from our results. During early stages of the endothelial lesion or loss, exposed basement membrane being rich in proteoglycans (5) can bind fibrinogen from circulation thus preventing its fibrinopeptide release even though it does not prevent thrombin binding (present studies). Thus, fibrinogen remains in atheromata (23) (24) (25) (26) and in the intima adjoining such or other conditions (23, 26) . Similarly, a possible role by such proteoglycans in thrombus formation and function can also be postulated. By tight binding to the basement membrane proteoglycans, the fibrin polymer is densely anchored, and this enhances its (noncovalent) stability and hemostatic effectiveness. Finally, the present findings raise the possibility offibrinopeptide binding by proteoglycans in blood or tissues thus making them inaccessible to the widely used fluid-phase measurements. Assuming such fluid phase binding does not impair their immunoassay (27) , binding by solid-phase proteoglycans, may influence their circulating levels and possibly account for the very short half life of fibrinopeptides.
The possible relationship of ClqI to circulating proteoglycans, which are increased in some disorders (2) and display anticoagulant properties in others (28) (29) (30) (31) (32) , is speculative, in that attempts to assay for a C lqI inhibitory activity were not made. Nevertheless, among this heterogeneous group chondroitin proteoglycans have been described (28, 34) . Most glycosaminoglycans identified as circulating anticoagulants enhanced the antithrombin III activity and thus were directed against thrombin; when examined further, evidence for heparan (29) , and keratan (29, 34) sulfate proteoglycans and for hyaluronic acid (30) was obtained in different patients. A chondroitin sulfate proteoglycan (28) differed from the others by impairing the thrombin release of fibrinopeptides, suggesting some similarity to the present form. These and other reported cases implied association with substantial neoplastic proliferation (28) (29) (30) (31) (32) (33) (34) and with parenchymal tissue destruction (31, 32) . Even so, keratan sulfate along with dermatan sulfate are known to be increased in mucopolysaccharide storage diseases but are not associated with a coagulopathy (33) . Increased circulating levels of proteoglycans occur in suramin treated patients (34) and among these, undersulfated chondroitin sulfate forms not unlike the present proteoglycan have been described. Along with abnormal accumulation ofproteoglycans in the liver of suramin-treated rats (35) , these findings intimated inhibition of enzymes which degrade proteoglycans. Thus, catabolic processes, as well as cell proliferation and tissue destruction appear to modulate their circulating levels in health and disease.
